WO2016027757A1 - Nouveau dérivé de 2-aminobenzoyle - Google Patents

Nouveau dérivé de 2-aminobenzoyle Download PDF

Info

Publication number
WO2016027757A1
WO2016027757A1 PCT/JP2015/073002 JP2015073002W WO2016027757A1 WO 2016027757 A1 WO2016027757 A1 WO 2016027757A1 JP 2015073002 W JP2015073002 W JP 2015073002W WO 2016027757 A1 WO2016027757 A1 WO 2016027757A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
hydrogen atom
solvate
Prior art date
Application number
PCT/JP2015/073002
Other languages
English (en)
Japanese (ja)
Inventor
健太郎 ▲高▼井
真吾 水嶋
昌一 島田
雪子 山本
Original Assignee
国立大学法人大阪大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人大阪大学 filed Critical 国立大学法人大阪大学
Priority to JP2016544191A priority Critical patent/JP6664814B2/ja
Publication of WO2016027757A1 publication Critical patent/WO2016027757A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Le problème abordé par cette invention est de pourvoir à un nouveau composé pour produire un effet sur un médicament destiné à traiter et/ou à prévenir les maladies mentales, telles que la dépression, la dépression atypique, la dépression résistant aux traitements, la névrose d'angoisse, les troubles bipolaires, un trouble obsessionnel compulsif, et le PTSD, des symptômes de douleur chronique tels que la fibromyalgie, et le prurit chronique, cet effet étant dû à la conversion d'un produit à structure métabolique qui est présent dans la voie métabolique du tryptophane. La solution selon l'invention porte sur un composé représenté par la formule (1) ou un sel pharmaceutiquement acceptable de celui-ci, ou un hydrate ou un solvate du composé ou du sel, et son utilisation en médecine. [Dans la formule, Q représente les formules (2a) à (2c) suivantes (où R1 est un atome d'hydrogène, et autre ; R2 et R3 sont identiques ou différents et sont choisis parmi un atome d'hydrogène, et autre, ou ensemble avec les atomes de carbone auxquels ils sont liés, ils forment éventuellement un cycle cycloalcane de 3 à 8 chaînons ; R4 et R5 sont identiques ou différents et sont choisis parmi un atome d'hydrogène, et autre, ou ensemble avec les atomes d'azote ils sont liés, ils forment éventuellement une amine cyclique ; et n est 0, 1, 2, 3, 4 ou 5)].
PCT/JP2015/073002 2014-08-18 2015-08-17 Nouveau dérivé de 2-aminobenzoyle WO2016027757A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2016544191A JP6664814B2 (ja) 2014-08-18 2015-08-17 新規２−アミノベンゾイル誘導体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014166140 2014-08-18
JP2014-166140 2014-08-18

Publications (1)

Publication Number Publication Date
WO2016027757A1 true WO2016027757A1 (fr) 2016-02-25

Family

ID=55350702

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2015/073002 WO2016027757A1 (fr) 2014-08-18 2015-08-17 Nouveau dérivé de 2-aminobenzoyle

Country Status (2)

Country Link
JP (1) JP6664814B2 (fr)
WO (1) WO2016027757A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019004292A1 (fr) * 2017-06-28 2019-01-03 国立大学法人大阪大学 Traitement de la douleur avec un agoniste de récepteur de la sérotonine-3

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3789072A (en) * 1970-04-22 1974-01-29 Squibb & Sons Inc Carboxamides
US4093734A (en) * 1975-11-03 1978-06-06 Boehringer Ingelheim Gmbh Amino-benzoic acid amides
JPH06510023A (ja) * 1991-04-18 1994-11-10 ユニバーシティ　オブ　ジョージア　リサーチ　ファウンデーション，インコーポレイテッド キヌレニナーゼの阻害剤
WO1997015550A1 (fr) * 1995-10-20 1997-05-01 Pharmacia & Upjohn S.P.A. Derives de l'acide benzoylpropionique substitues par fluoro
JPH10503525A (ja) * 1995-01-09 1998-03-31 チョン クン ダン コーポレイション カンプトテシン誘導体及びその製造方法
JP2002536434A (ja) * 1999-02-10 2002-10-29 イーライ・リリー・アンド・カンパニー ５−ｈｔ１ｆアゴニスト
JP2007518673A (ja) * 2003-06-26 2007-07-12 ニューリム ファーマシューティカルズ（１９９１）リミテッド ２−アミノベンゾイル誘導体
JP2008546651A (ja) * 2005-06-14 2008-12-25 メルク フロスト カナダ リミテツド モノアミンオキシダーゼａ及びｂの可逆的阻害剤
JP2010505816A (ja) * 2006-10-03 2010-02-25 ヌリム・ファーマスーティカルズ・（１９９１）・リミテッド 治療薬剤としての置換アリール−インドール化合物とそのキヌレニン／キヌラミン様代謝産物
WO2013151707A1 (fr) * 2012-04-05 2013-10-10 Chdi Foundation, Inc. Inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3789072A (en) * 1970-04-22 1974-01-29 Squibb & Sons Inc Carboxamides
US4093734A (en) * 1975-11-03 1978-06-06 Boehringer Ingelheim Gmbh Amino-benzoic acid amides
JPH06510023A (ja) * 1991-04-18 1994-11-10 ユニバーシティ　オブ　ジョージア　リサーチ　ファウンデーション，インコーポレイテッド キヌレニナーゼの阻害剤
JPH10503525A (ja) * 1995-01-09 1998-03-31 チョン クン ダン コーポレイション カンプトテシン誘導体及びその製造方法
WO1997015550A1 (fr) * 1995-10-20 1997-05-01 Pharmacia & Upjohn S.P.A. Derives de l'acide benzoylpropionique substitues par fluoro
JP2002536434A (ja) * 1999-02-10 2002-10-29 イーライ・リリー・アンド・カンパニー ５−ｈｔ１ｆアゴニスト
JP2007518673A (ja) * 2003-06-26 2007-07-12 ニューリム ファーマシューティカルズ（１９９１）リミテッド ２−アミノベンゾイル誘導体
JP2008546651A (ja) * 2005-06-14 2008-12-25 メルク フロスト カナダ リミテツド モノアミンオキシダーゼａ及びｂの可逆的阻害剤
JP2010505816A (ja) * 2006-10-03 2010-02-25 ヌリム・ファーマスーティカルズ・（１９９１）・リミテッド 治療薬剤としての置換アリール−インドール化合物とそのキヌレニン／キヌラミン様代謝産物
WO2013151707A1 (fr) * 2012-04-05 2013-10-10 Chdi Foundation, Inc. Inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BACK W., ARCHIV DER PHARMAZIE, vol. 303, no. 6, 1970, pages 465 - 470, ISSN: 0376-0367 *
MAKINO K. ET AL., SCIENCE, vol. 120, 1954, pages 544 - 545, ISSN: 0036-8075 *
MUELLER P. ET AL., ARCH. PHARM. ( WEINHEIM, vol. 316, no. 8, 1983, pages 707 - 712, ISSN: 0365-6233 *
PERTZ H. ET AL., PHARM.ACTA HELV., vol. 63, no. 4-5, 1988, pages 128 - 131, ISSN: 0031-6865 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019004292A1 (fr) * 2017-06-28 2019-01-03 国立大学法人大阪大学 Traitement de la douleur avec un agoniste de récepteur de la sérotonine-3
CN111050800A (zh) * 2017-06-28 2020-04-21 国立大学法人大阪大学 血清素3受体激动剂对疼痛的治疗
JPWO2019004292A1 (ja) * 2017-06-28 2020-04-30 国立大学法人大阪大学 セロトニン３受容体アゴニストによる疼痛の治療
EP3646886A4 (fr) * 2017-06-28 2020-05-06 Osaka University Traitement de la douleur avec un agoniste de récepteur de la sérotonine-3
JP7090344B2 (ja) 2017-06-28 2022-06-24 国立大学法人大阪大学 セロトニン３受容体アゴニストによる疼痛の治療
US11446290B2 (en) 2017-06-28 2022-09-20 Osaka University Treatment of pain with serotonin-3 receptor agonist

Also Published As

Publication number Publication date
JP6664814B2 (ja) 2020-03-13
JPWO2016027757A1 (ja) 2017-07-20

Similar Documents

Publication Publication Date Title
US9884844B2 (en) Heterocyclic compounds and methods of use thereof
EP1218359B1 (fr) Derives de piperazine utilises comme antagonistes de tachykinines
CA2428039C (fr) Agents serotoninergiques
JP6843114B2 (ja) ムスカリン作動薬
JP2019510026A (ja) 複素環化合物
JP6611736B2 (ja) 疼痛に対する多様な活性を有する１−オキサ−４，９−ジアザスピロウンデカン化合物のアルキル誘導体
CN110088107B (zh) 化合物、组合物及其用途
JP2010529117A (ja) 代謝型グルタミン酸受容体オキサジアゾールリガンドおよびそれらの増強剤としての使用
JP6975515B2 (ja) Ｔｒｐａ１モデュレーターとしてのスルホニルシクロアルキルカルボキサミド化合物
JP2017516819A (ja) 疼痛に対する多様な活性を有する１−オキサ−４，９−ジアザスピロウンデカン化合物のアルキルおよびアリール誘導体
AU2002237654A1 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (CNS) disorders
JP6203841B2 (ja) カルバメート／尿素誘導体
CN112118838A (zh) 非外消旋混合物及其用途
JPWO2006028161A1 (ja) セロトニン５−ｈｔ３受容体作動薬
JP2017516817A (ja) 疼痛に対する多様な活性を有する１−オキサ−４，９−ジアザスピロウンデカン化合物のアミド誘導体
JP2018530582A (ja) 選択的ｎｒ２ｂアンタゴニスト
CA3103929A1 (fr) Pyrazoles substitues par phenyle utilises en tant que modulateurs de roryt
US11077090B2 (en) Compounds and compositions and uses thereof
JP6664814B2 (ja) 新規２−アミノベンゾイル誘導体
WO2009119528A1 (fr) Composé hétérocyclique
WO2021132311A1 (fr) Dérivé amide d'acide aliphatique
US7816362B2 (en) Serotonergic agents
CN113784755A (zh) 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物
BR112018007289B1 (pt) Compostos de derivado de oxadiazol amina como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
ZA200304994B (en) Piperazine derivatives, their preparation and their use for treating central nervous systems (CNS) disorders.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15834285

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2016544191

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15834285

Country of ref document: EP

Kind code of ref document: A1